Investing

RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202

By June 4, 2025

Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!

Your name
Your email

By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.
Popular

About Freedigitalmarkets
Latest Posts
Calendar
June 2025

M T W T F S S

1

2 3 4 5 6 7 8

9 10 11 12 13 14 15

16 17 18 19 20 21 22

23 24 25 26 27 28 29

30

« May Jul »

Disclaimer: freedigitalmarkets.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Top

RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202

Locksley Resources LimitedAppointment of Experienced Geologist Ian Stockton to Board

Nextech3D.ai Poised for Growth as Event-Tech and 3D/AR Revenue Accelerates

Americas Gold & Silver to Acquire Crescent Silver in US$65 Million Deal

Locksley Resources LimitedAppointment of Experienced Geologist Ian Stockton to Board

Senior Loan Facility Refinanced with Nebari

Nextech3D.ai Poised for Growth as Event-Tech and 3D/AR Revenue Accelerates

RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202

Related Posts